|
Operative time, min, mean ± SD
|
262.6 ± 57.1
|
175.6 ± 45.5
|
0.000
|
264.1 ± 55.7
|
206.9 ± 64.0
|
0.001
|
|
Ischemic time, min, mean ± SD
|
35.9 ± 10.8
|
22.8 ± 7.3
|
0.000
|
34.8 ± 9.4
|
32.8 ± 7.2
|
0.342
|
|
Estimated blood loss, ml, mean ± SD
|
212.6 ± 94.2
|
179.1 ± 123.6
|
0.005
|
208.3 ± 93.8
|
230.7 ± 135.7
|
0.696
|
|
Entry into sinus (n, %)
|
19 (61.3%)
|
63 (19.7%)
|
0.000
|
17 (58.6%)
|
14 (48.3%)
|
0.430
|
|
Conversions (n, %)
| | | | | | |
|
Open conversion
|
0 (0.0%)
|
2 (0.6%)
|
1.000
|
0 (0.0%)
|
0 (0.0%)
|
–
|
|
Radical conversion
|
1 (3.2%)
|
6 (1.9%)
|
1.000
|
1 (3.4%)
|
1 (3.4%)
|
1.000
|
|
Length of stay, d, mean ± SD
|
7.9 ± 1.4
|
7.9 ± 2.0
|
0.429
|
7.8 ± 1.4
|
8.6 ± 2.3
|
0.370
|
|
Postoperative complications (n, %)
|
4 (12.9%)
|
35 (10.9%)
|
0.973
|
4 (13.8%)
|
7 (24.1%)
|
0.315
|
|
Clavien 1–2
|
4 (12.9%)
|
31 (9.7%)
| |
4 (13.8%)
|
6 (20.7%)
| |
|
Clavien 3–4
|
0 (0.0%)
|
4 (1.3%)
| |
0 (0.0%)
|
1 (3.4%)
| |
|
Tumor histology (n, %)
| | |
1.000
| | |
0.703
|
|
Malignant
|
28 (90.3%)
|
286 (89.4%)
| |
26 (89.7%)
|
24 (82.8%)
| |
|
Benign
|
3 (9.7%)
|
34 (10.6%)
| |
3 (10.3%)
|
5 (17.2%)
| |
|
Positive margins (n, %)
|
1 (3.2%)
|
5 (1.6%)
|
1.000
|
1 (3.4%)
|
0 (0.0%)
|
1.000
|
|
Postoperative eGFR, ml/min/1.73m2, median (IQR)
| | | | | | |
|
3 months
|
93 (73–108)
|
92 (79–110)
|
0.670
|
93 (74–107)
|
84 (60–105)
|
0.287
|
|
12 months
|
88 (73–114)
|
93 (81–112)
|
0.453
|
88 (77–108)
|
80 (61–98)
|
0.186
|
|
Acute renal injury (n, %)
|
1 (3.2%)
|
3 (0.9%)
|
0.795
|
0 (0.0%)
|
1 (3.4%)
|
1.000
|
|
Postoperative change in eGFR, %, median (IQR)
| | | | | | |
|
3 months
|
− 6.3 (− 11.3 to − 2.4)
|
− 3.2 (− 19.4 to − 2.3)
|
0.849
|
− 6.3 (− 10.3 to − 2.4)
|
− 12.0 (− 17.5 to − 6.7)
|
0.018
|
|
12 months
|
− 5.8 (− 15.5 to 1.9)
|
− 2.0 (− 17.4 to 10.0)
|
0.551
|
− 5.8 (− 12.7 to 0.1)
|
− 11.7 (− 18.9 to − 4.0)
|
0.038
|
|
CKD upstaging n (%)
|
6 (19.4%)
|
68 (21.3%)
|
0.805
|
5 (17.2%)
|
12 (41.4%)
|
0.043
|
